CAR T-cell therapy targeting CD19 is effective for leukemias because the body can tolerate the loss of healthy B cells expressing CD19.

“What just turns out to be serendipitous is that the body can tolerate those cells going away. And so what has made this a particularly effective and safe and relatively well tolerated treatment for cancer is that the collateral damage is actually not that damaging.”